85
Participants
Start Date
April 7, 2020
Primary Completion Date
July 12, 2023
Study Completion Date
June 24, 2024
14 mg AFM24
14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
40 mg AFM24
40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
80 mg AFM24
80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
160 mg AFM24
160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
320 mg AFM24
320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
480 mg AFM24
480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
720 mg AFM24
720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Seoul National University Bundang Hospital, Seongnam-si
University Hospital Hamburg-Eppendorf, Hamburg
University Hospital Foundation Jimenez Diaz, Madrid
University Hospital HM Sanchinarro, Madrid
University Duisburg-Essen, University Hospital Essen, Essen
Hospital Clinic Universitario Biomedical Research institute INCLIVA, Valencia
Nordwest Hospital GmbH, Frankfurt am Main
University of Southern California, Los Angeles
Dana Faber Cancer Institute, Boston
Samsung Medical Center, Seoul
The Catholic University of Korea St. Vincent's Hospital, Suwon
Institute of Cancer Research - Royal Marsden, London
Vall d'Hebron Institute of Oncology, Barcelona
Lead Sponsor
Affimed GmbH
INDUSTRY